Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas
Presentation - Q2 2024
Mission
We invest in and build companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. We differentiate ourselves by using our network, expertise and resources to achieve long-term success for our companies. We have the utmost respect for all our stakeholders and strive to be described by them as a great partner.
Latest Portfolio Company News
Latest Press Releases
Interim report Q2 2024
The interim report for the second quarter 2024 was published on Wednesday July 17 at 08:00 CEST.
Presentation: the same day at 14:00 CEST.